Neurocrine Biosciences | NBIX - Trade Debtors


Neurocrine Biosciences reported $768.1M in Trade Debtors for its fiscal quarter ending in March of 2026.





Trade Debtors Change Date
AbbVie USD 12.59B 180M Dec/2025
Acadia Pharmaceuticals USD 148.38M 153K Mar/2026
Agios Pharmaceuticals USD 16.13M 5.56M Mar/2026
ALKERMES USD 407.63M 73.6M Mar/2026
Alnylam Pharmaceuticals USD 883.96M 106.39M Mar/2026
Amgen USD 9.14B 432M Mar/2026
Biogen USD 1.79B 76.6M Mar/2026
BioMarin Pharmaceutical USD 903.91M 4.3M Mar/2026
Cytokinetics USD 6.83M 10.94M Mar/2026
Enanta Pharmaceuticals USD 40.16M 1.52M Dec/2024
Exelixis USD 328.95M 42.03M Mar/2026
Gilead Sciences USD 4.74B 172M Mar/2026
Halozyme Therapeutics USD 457.99M 16.72M Mar/2026
Incyte USD 1.05B 27.09M Mar/2026
Ionis Pharmaceuticals USD 74M 8M Mar/2026
Nektar Therapeutics USD 1.78M 1.12M Dec/2025
Neurocrine Biosciences USD 768.1M 81.3M Mar/2026
Pfizer USD 16.17B 332M Mar/2026
Prothena USD 5.16M 0 Dec/2023
Regeneron Pharmaceuticals USD 5.73B 10.1M Mar/2026
Repligen USD 151.55M 7.03M Mar/2026
Rigel Pharmaceuticals USD 28.9M 1.39M Jun/2024
Sarepta Therapeutics USD 547.91M 149.68M Mar/2026
Teva Pharmaceutical Industries USD 3.39B 316M Mar/2026
Ultragenyx Pharmaceutical USD 60M 98M Mar/2026
Vertex Pharmaceuticals USD 2B 56.7M Mar/2026
Xoma USD 14.78M 4.96M Jun/2024